A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo-controlled, double-blind, multi-site study in which up to
approximately 36 subjects with a recent C. difficile infection (CDI) who have completed a
standard of care course of CDI antibiotics and have achieved clinical cure based on signs and
symptoms, will be randomized to 7 or 28 daily doses of ART24 or placebo. Subjects will be
followed for 6 months after the last dose of study drug.